Samedan Ltd Pharmaceutical Publishers

Archive of previous issues

Subscribe ONLINE

Pharmaceutical Industry Comprehensive Directory

Industry Events Calendar

News and Press Releases

Employment Opportunities

Advertising with us

Air Transport Publications

home > ebr > spring 2004 > what is a cancer drug worth?

PUBLICATIONS

European BioPharmaceutical Review What is a Cancer Drug Worth?
Frequently, the specific merits of individual companies are overlooked as the values of those companies fluctuate along with the broader stock markets of which they are constituents. So too are the values of licensing deals governed by external factors that are quite unrelated to the true 'worth' of the drugs being licensed. This is as true of deals for development-stage oncology products as it is for any other type of licensing agreement, but the huge number of variables involved in this - one of the most inscrutable of therapy areas - makes searching for appropriate deal terms all the more difficult. The following analysis looks at some recent cancer deals and explores some of the determining variables that influenced the headline values of those deals.
Read full article >>



Rate this article	You must be a member of the site to make a vote.	Average rating:	0

There are no comments in regards to this article.

Post a comment

Read all comments

Rupert Winckler is a Consultant with PharmaVentures, a UK-based pharmaceutical strategy consultancy he joined in 2001. He gained his degree in Molecular and Cellular Biochemistry from the University of Oxford and holds a Diploma in Financial Management from the ACCA. Prior to joining PharmaVentures, he worked for the London Stock Exchange, the Securities and Futures Authority, and the Forensic Accounting division of KPMG.